Beaumont Hospital

Futó vizsgálatok

• Még nem toboroz

  Safety and Efficacy of VX-828/Deutivacaftor Combination Therapy With and Without Tezacaftor in Subjects With Cystic Fibrosis

  2025-523400-72-00· 2. fázis· Vertex Pharmaceuticals Inc.· Forrás

• Toboroz

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  2024-518365-10-00· 3. fázis· F. Hoffmann-La Roche AG· Forrás

• Még nem toboroz

  A phase II clinical trial of neoadjuvant treatment with Ivonescimab and chemotherapy for stage IIA-IIB-IIIA and IIIB (T3N2) non-small cell lung cancer (NSCLC) patients

  2026-525303-27-00· 2. fázis· Fundacion GECP· Forrás

• Toboroz

  Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC

  NCT07158489· 2. fázis· Swiss Cancer Institute· Forrás

• Toboroz

  A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)

  2025-521587-35-00· 3. fázis· Summit Therapeutics Inc.· Forrás

• Még nem toboroz

  HOVON 168:Study on epcoritamab in frail patients with diffuse large B-Cell lymphoma (DLBCL) who have not been treated before

  2025-524230-25-00· 2. fázis· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Forrás

• Toboroz

  Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS (PREVAiLS)

  2025-524002-16-00· 3. fázis· Ferrer Internacional S.A.· Forrás

• Toboroz

  A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)

  NCT07221669· 3. fázis· Biogen· Forrás

• Toboroz

  A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis

  2025-521546-23-00· 3. fázis· Novartis Pharma AG· Forrás

• Toboroz

  A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

  NCT07326709· 3. fázis· Novartis Pharmaceuticals· Forrás

• Toboroz

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· 3. fázis· Bristol-Myers Squibb· Forrás

• Toboroz

  A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma

  NCT07456033· 3. fázis· GlaxoSmithKline· Forrás

• Toboroz

  A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  NCT07218341· 4. fázis· Eli Lilly and Company· Forrás

• Toboroz

  Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  NCT07223814· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás

• Toboroz

  A Pivotal Study Evaluating Safety and Effectiveness of Adaptative Tip Catheter in Patients With Acute Ischemic Stroke

  NCT07367100· Neuravi Limited· Forrás

• Toboroz

  A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy

  NCT06931717· 3. fázis· ETOP IBCSG Partners Foundation· Forrás

• Toboroz

  A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

  NCT06932562· 3. fázis· European Myeloma Network B.V.· Forrás

• Toboroz

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· 3. fázis· Eli Lilly and Company· Forrás

• Toboroz

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· 3. fázis· Hoffmann-La Roche· Forrás

• Toboroz

  Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

  NCT07023835· 2. fázis· Zydus Therapeutics Inc.· Forrás

• Toboroz

  Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  NCT06982521· 3. fázis· Relay Therapeutics, Inc.· Forrás

• Toboroz

  A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

  NCT06863272· 1/2. fázis· Merck Sharp & Dohme LLC· Forrás

• Fut, nem toboroz

  A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

  NCT06880744· 3. fázis· AbbVie· Forrás

• Toboroz

  A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)

  2023-510294-34-00· 3. fázis· University Of Cologne· Forrás

• Toboroz

  Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors

  NCT05974774· 3. fázis· European Organisation for Research and Treatment of Cancer - EORTC· Forrás

• Toboroz

  A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

  NCT06499285· 3. fázis· Takeda· Forrás

• Toboroz

  Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  NCT06881784· 3. fázis· Revolution Medicines, Inc.· Forrás

• Toboroz

  Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

  NCT06652438· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás

• Toboroz

  A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

  NCT06875310· 3. fázis· Mirati Therapeutics Inc.· Forrás

• Toboroz

  A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

  NCT06890884· 2. fázis· Merck Sharp & Dohme LLC· Forrás

• Toboroz

  A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

  NCT06868277· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

  NCT06764485· 3. fázis· Celgene· Forrás

• Toboroz

  An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis

  2023-507853-13-00· 2. fázis· Eli Lilly & Co.· Forrás

• Toboroz

  An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis

  NCT06764693· AbbVie· Forrás

• Toboroz

  FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

  NCT06788990· 2/3. fázis· Bicara Therapeutics· Forrás

• Toboroz

  A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

  NCT06284317· 3. fázis· ETOP IBCSG Partners Foundation· Forrás

• Fut, nem toboroz

  Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

  NCT06760637· 3. fázis· Pfizer· Forrás

• Toboroz

  A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

  NCT06227910· 3. fázis· Takeda· Forrás

• Fut, nem toboroz

  Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

  NCT06635824· 3. fázis· Genmab· Forrás

• Toboroz

  Measurement and Impact of Physical Impairment in Amyotrophic Lateral Sclerosis: Use of Digital Technologies - A Precision ALS Project

  NCT06820008· University of Dublin, Trinity College· Forrás

• Fut, nem toboroz

  A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

  NCT06643481· 2. fázis· Novartis Pharmaceuticals· Forrás

• Fut, nem toboroz

  A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

  NCT06598943· 2. fázis· Eli Lilly and Company· Forrás

• Toboroz

  Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

  NCT06548542· 2. fázis· AbbVie· Forrás

• Fut, nem toboroz

  A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

  NCT06365853· 2. fázis· AbbVie· Forrás

• Fut, nem toboroz

  A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

  NCT06388733· 3. fázis· Ivy Brain Tumor Center· Forrás

• Toboroz

  A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer

  NCT06320067· 3. fázis· University College, London· Forrás

• Toboroz

  A study to discover if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet

  2023-506150-21-00· 2. fázis· Dr. Falk Pharma GmbH· Forrás

• Toboroz

  Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

  NCT05950945· 3. fázis· Daiichi Sankyo· Forrás

• Fut, nem toboroz

  U011 - Wireless Ultra Long-Term EEG Recordings in Epilepsy

  NCT05915988· UNEEG Medical A/S· Forrás

• Fut, nem toboroz

  Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

  NCT05899608· 3. fázis· Summit Therapeutics· Forrás

Showing 50 of 84.

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Tüdőrák12 toboroz
• Amiotrófiás laterálszklerózis (ALS)3 toboroz
• Áttétes emlőrák3 toboroz
• Krónikus limfoid leukémia (CLL)3 toboroz
• Akut mieloid leukémia (AML)2 toboroz
• Crohn-betegség2 toboroz
• Diffúz nagy B-sejtes limfóma (DLBCL)2 toboroz
• Huntington-kór2 toboroz
• Prosztatarák2 toboroz
• Stroke (szélütés)2 toboroz
• Vastagbélrák2 toboroz
• Arthritis psoriatica1 toboroz
• Asztma1 toboroz
• Cisztás fibrózis1 toboroz
• Coeliac disease1 toboroz
• Fej-nyaki daganatok1 toboroz
• Glioblasztóma1 toboroz
• Idiopátiás tüdőfibrózis1 toboroz
• Mielodiszplasztikus szindróma (MDS)1 toboroz
• Mielóma multiplex1 toboroz
• Pikkelysömör1 toboroz
• Sclerosis multiplex (SM)1 toboroz
• Spinális izomatrófia (SMA)1 toboroz
• Tripla negatív emlőrák1 toboroz

Lezárt vizsgálatok

• Toboroz

  A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)

  2024-518296-56-00· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Fut, nem toboroz

  Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

  NCT06726265· 3. fázis· Immutep S.A.S.· Forrás

• Lezárult

  A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome

  NCT06312020· 2. fázis· Horizon Therapeutics Ireland Designated Activity Company· Forrás

• Fut, nem toboroz

  A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

  NCT06422884· 2. fázis· Endeavor Biomedicines, Inc.· Forrás

• Fut, nem toboroz

  A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

  NCT06190951· 2. fázis· Regeneron Pharmaceuticals· Forrás

• Lezárult

  A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered in participants with PD-L1 ≥ 1% TC Stage IIB, IIIA, or select IIIB (T3N2 only) NSCLC following resection and adjuvant platinum-based chemotherapy

  2023-506696-10-00· 3. fázis· F. Hoffmann-La Roche AG· Forrás

• Fut, nem toboroz

  Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

  NCT06211036· 3. fázis· Amgen· Forrás

• Toboroz

  A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

  NCT06430801· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Fut, nem toboroz

  A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

  NCT06257875· 2. fázis· AbbVie· Forrás

• Fut, nem toboroz

  A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy

  NCT05979311· 3. fázis· ViiV Healthcare· Forrás

• Toboroz

  A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

  NCT06091865· 3. fázis· Regeneron Pharmaceuticals· Forrás

• Lezárult

  A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease

  NCT06001177· 2. fázis· Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA· Forrás

• Fut, nem toboroz

  Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status

  NCT05673187· 2. fázis· ETOP IBCSG Partners Foundation· Forrás

• Fut, nem toboroz

  Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

  NCT05740566· 3. fázis· Amgen· Forrás

• Lezárult

  A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effects of PTC857 in Adult Subjects With Amyotrophic Lateral Sclerosis (CARDINALS)

  NCT05349721· 2. fázis· PTC Therapeutics Inc.· Forrás

• Lezárult

  ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

  NCT05507216· 3. fázis· Abivax S.A.· Forrás

• Lezárult

  Extension Study Evaluating The Safety And Tolerability of AMX0035

  NCT05619783· 3. fázis· Amylyx Pharmaceuticals Inc.· Forrás

• Lezárult

  A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

  NCT05614063· 3. fázis· Xenon Pharmaceuticals Inc.· Forrás

• Fut, nem toboroz

  Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

  NCT05456685· 2. fázis· AbbVie· Forrás

• Fut, nem toboroz

  Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)

  NCT05224141· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Lezárult

  Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

  NCT05064358· 2. fázis· GlaxoSmithKline· Forrás

• Fut, nem toboroz

  CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.

  NCT04667663· 1. fázis· Cancer Trials Ireland· Forrás

• Lezárult

  A study to investigate the safety and efficacy of AMX0035 in patients with Amyotrophic Lateral Sclerosis

  NCT05021536· 3. fázis· Amylyx Pharmaceuticals Inc.· Forrás

• Lezárult

  A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis

  NCT04973137· 3. fázis· Prothena Biosciences Limited· Forrás

• Lezárult

  Lighthouse II study

  NCT05193994· 3. fázis· Stichting TRICALS Foundation· Forrás

• Fut, nem toboroz

  A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

  NCT04736706· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Fut, nem toboroz

  Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

  NCT04685135· 3. fázis· Mirati Therapeutics Inc.· Forrás

• Lezárult

  A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

  NCT04623775· 2. fázis· Bristol-Myers Squibb· Forrás

• Lezárult

  Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

  NCT04736173· 2. fázis· Arcus Biosciences, Inc.· Forrás

• Lezárult

  Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

  NCT04662710· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Lezárult

  Phase 3 Study of Pembrolizumab/Placebo plus Enzalutamide plus ADT in mHSPC

  NCT04191096· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Lezárult

  A Prospective Phase III Multi-center, 2-Year Placebo Controlled, Double Blind Study to Evaluate the Efficacy and Safety of "Kamada-AAT for Inhalation" 80 mg per day in Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation (40% ≤ FEV1 ≤ 80% of predicted; FEV1/SVC ≤ 70%), Followed by a 2-Year Open-Label Extension

  NCT04204252· 3. fázis· Kamada Ltd.· Forrás

• Fut, nem toboroz

  An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

  NCT03844048· 3. fázis· AbbVie· Forrás

• Lezárult

  Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC

  NCT03834493· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Lezárult

  Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)

  NCT03675737· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Lezárult

  A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03524092· 3. fázis· Eli Lilly and Company· Forrás

• Lezárult

  Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

  NCT03615326· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Lezárult

  Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease

  2024-511553-22-00· 3. fázis· Celgene International II SARL· Forrás

• Lezárult

  Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn's Disease

  2023-510426-33-00· 3. fázis· Celgene International II S.a.r.l.· Forrás

• Lezárult

  An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

  NCT03518086· 3. fázis· Eli Lilly and Company· Forrás

• Lezárult

  Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

  NCT03409614· 3. fázis· Regeneron Pharmaceuticals· Forrás

• Lezárult

  A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

  NCT03069352· 3. fázis· AbbVie· Forrás

• Lezárult

  Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

  NCT02914535· 3. fázis· Alfasigma S.p.A.· Forrás

• Fut, nem toboroz

  A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

  NCT03006068· 3. fázis· AbbVie· Forrás

• Lezárult

  Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

  NCT02950051· 3. fázis· German CLL Study Group· Forrás

• Lezárult

  Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke

  NCT02898610· 3. fázis· University College Dublin· Forrás

• Lezárult

  A study of nivolumab or placebo in patients following removal of their esophageal or gastroesophageal junction cancer.

  NCT02743494· 3. fázis· Bristol Myers Squibb International Corporation· Forrás

• Lezárult

  Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1

  NCT02620280· 3. fázis· Fondazione Michelangelo· Forrás

• Lezárult

  A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion

  NCT02398656· 3. fázis· University of Calgary· Forrás

• Lezárult

  A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT01848561· AbbVie· Forrás

Showing 50 of 52.

Betegségek

Betegségek, amelyekről az intézmény publikál vagy amelyekre vizsgálatot futtat.

• Dystonia8 munka · 0 vizsgálat